Sarepta Therapeutics | SRPT - Sales Revenues

Sarepta Therapeutics reported $396.78M in Sales Revenues for its fiscal quarter ending in December of 2023.

Sales Change Date
Acadia Pharmaceuticals USD 231.04M 19.34M Dec/2023
Agios Pharmaceuticals USD 7.1M 296K Dec/2023
Alnylam Pharmaceuticals USD 439.72M 310.81M Dec/2023
Amgen USD 8.2B 1.29B Dec/2023
Biogen USD 2.29B 96.3M Mar/2024
BioMarin Pharmaceutical USD 649M 2.79M Mar/2024
Daiichi Sankyo JPY 409.62B 37.3B Mar/2024
Eli Lilly USD 9.35B 145.2M Dec/2023
Gilead Sciences USD 7.12B 64M Dec/2023
Incyte USD 1.01B 94.32M Dec/2023
Insmed USD 83.69M 4.62M Dec/2023
Ionis Pharmaceuticals USD 325M 180.79M Dec/2023
Moderna USD 2.81B 980M Dec/2023
Neurocrine Biosciences USD 515.2M 16.4M Dec/2023
Pfizer USD 14.25B 1.02B Dec/2023
PTC Therapeutics USD 210.12M 96.94M Mar/2024
Regeneron Pharmaceuticals USD 3.43B 71.6M Dec/2023
Roche Holding CHF 28.94B 842M Dec/2023
Sanofi EUR 10.92B 1.05B Dec/2023
Sarepta Therapeutics USD 396.78M 64.96M Dec/2023
Ultragenyx Pharmaceutical USD 127.39M 29.34M Dec/2023
Vertex Pharmaceuticals USD 2.52B 34.2M Dec/2023